基石药业-B(02616)：舒格利单抗III期小细胞肺癌新适应症获英国MHRA批准

智通财经网02-23

智通财经APP讯，基石药业-B(02616)发布公告，舒格利单抗的新适应症申请已获英国药品和医疗保健用品管理局(MHRA)批准单药用于治疗肿瘤细胞PD-L1表达≥1%、无表皮生长因数受体(EGFR)敏感突变或ALK、ROS1基因组变异、在含铂放化疗(CRT)后未出现疾病进展的、不可切除的III期小细胞肺癌(NSCLC)成人患者。继欧盟委员会(EC)批准后，舒格利单抗III期NSCLC新适应症再获...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2613027209?lang=zh_CN&edition=full","thumbnail":"https://img.zhitongcaijing.com/gonggao/ztcj_announce_48.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","is_english":false,"pubTime":"2026-02-23 08:17","share_image_url":"https://static.laohu8.com/6ca2dcdccfa2217fb20a0351f4efe814","id":"2613027209","market":"sg","top_or_hot":-1,"title":"基石药业-B(02616)：舒格利单抗III期小细胞肺癌新适应症获英国MHRA批准","media":"智通财经网","content":"<div>\n<p>智通财经APP讯，基石药业-B(02616)发布公告，舒格利单抗的新适应症申请已获英国药品和医疗保健用品管理局(MHRA)批准单药用于治疗肿瘤细胞PD-L1表达≥1%、无表皮生长因数受体(EGFR)敏感突变或ALK、ROS1基因组变异、在含铂放化疗(CRT)后未出现疾病进展的、不可切除的III期小细胞肺癌(NSCLC)成人患者。继欧盟委员会(EC)批准后，舒格利单抗III期NSCLC新适应症再获...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1406210.html\">网页链接</a>\n\n</div>\n","source":"highlight_zhitongcaijin","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>基石药业-B(02616)：舒格利单抗III期小细胞肺癌新适应症获英国MHRA批准</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n基石药业-B(02616)：舒格利单抗III期小细胞肺癌新适应症获英国MHRA批准\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-23 08:17 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1406210.html><strong>智通财经网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，基石药业-B(02616)发布公告，舒格利单抗的新适应症申请已获英国药品和医疗保健用品管理局(MHRA)批准单药用于治疗肿瘤细胞PD-L1表达≥1%、无表皮生长因数受体(EGFR)敏感突变或ALK、ROS1基因组变异、在含铂放化疗(CRT)后未出现疾病进展的、不可切除的III期小细胞肺癌(NSCLC)成人患者。继欧盟委员会(EC)批准后，舒格利单抗III期NSCLC新适应症再获...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1406210.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02616","symbol_name":"基石药业-B","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1406210.html","article_id":"2613027209","we_media_id":null,"thumbnails":["https://img.zhitongcaijing.com/gonggao/ztcj_announce_48.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2613027209","pubTimestamp":1771805849,"columns":[],"sourceInfo":{"source_id":"highlight_zhitongcaijin","name":"智通财经网"},"weMediaInfo":null,"summary":"基石药业-B(02616)发布公告，舒格利单抗的新适应症申请已获英国药品和医疗保健用品管理局(MHRA)批准单药用于治疗肿瘤细胞PD-L1表达≥1%、无表皮生长因数受体(EGFR)敏感突变或ALK、ROS1基因组变异、在含铂放化疗(CRT)后未出现疾病进展的、不可切除的III期小细胞肺癌(NSCLC)成人患者。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"02616":"基石药业-B","BK4134":"信息科技咨询与其它服务","III":"信息服务","BK1161":"生物科技","BK1574":"生物医药B类股"},"translate_title":"CStone Pharmaceuticals-B (02616): Sugalimab's new indication for stage III small cell lung cancer was approved by the UK MHRA","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02616":1.5,"III":1.5},"content_text":"智通财经APP讯，基石药业-B(02616)发布公告，舒格利单抗的新适应症申请已获英国药品和医疗保健用品管理局(MHRA)批准单药用于治疗肿瘤细胞PD-L1表达≥1%、无表皮生长因数受体(EGFR)敏感突变或ALK、ROS1基因组变异、在含铂放化疗(CRT)后未出现疾病进展的、不可切除的III期小细胞肺癌(NSCLC)成人患者。继欧盟委员会(EC)批准后，舒格利单抗III期NSCLC新适应症再获英国MHRA批准，这是该产品在英国获得的第二个适应症批准。此次获批是基于GEMSTONE-301这项多中心、随机、双盲的III期临床研究，该研究证实舒格利单抗能为III期NSCLC患者带来具有统计学意义的无进展生存期(PFS)改善和具有临床意义的总生存期(OS)延长。舒格利单抗已在欧洲、中东及非洲、拉丁美洲达成四项商业化合作，累计覆盖六十余个国家和地区，海外的商业化工作正在积极开展中。基石药业首席执行官、研发总裁及执行董事杨建新博士表示：“舒格利单抗自2024年7月在欧洲获批上市，现已成为欧洲唯二获批用于III期NSCLC的PD-(L)1抗体，实现了从III期到IV期NSCLC全病程的覆盖。目前，舒格利单抗的商业化版图已拓展至全球六十余个国家和地区，市场准入申请已在十余个国家获批或进入审批流程，且已成功纳入多个国家的医保报销范围，再次证舒格利单抗的临床价值和药物经济学获益。”基石药业首席医学官史青梅博士表示：“此次MHRA对舒格利单抗III期NSCLC新适应症的批准是国际监管机构对其临床价值的进一步肯定，将有力助推该产品的全球商业潜力释放。同时，我们也为基石药业临床开发和注册团队高效的执行力、宝贵的全球注册经验以及成功适应欧洲与英国成熟监管体系的能力而深感自豪。目前，舒格利单抗联合化疗用于IV期NSCLC已获《欧洲肿瘤内科学会(ESMO)非驱动基因阳性转移性非小细胞肺癌动态临床指南》最高等级【I,  A】的一线治疗推荐，我们期待其III期NSCLC新适应症在不久的将来也能获得该权威指南推荐。此外，基石药业还将推进舒格利单抗用于胃癌(GC)、食管鳞癌(ESCC)等新适应症的注册申报。”","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2613027209","isCrawlerRequest":true}